NCT04885426|UnknownDMC
Metformin for the Prevention of CRA Recurrence
The Role of Metformin in the Prevention for Colorectal Adenoma Recurrence in Post-polypectomy Patients
Loading search results
The Role of Metformin in the Prevention for Colorectal Adenoma Recurrence in Post-polypectomy Patients
Sponsor study identifier
interventional
414
1 country
1
Study Start
August 1, 2020
Actual (reported)Primary Completion
November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 1, 2020
Actual (reported)November 29, 2020
Actual (reported)May 13, 2021
Actual (reported)November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
CRA recurrence rate
Percentage of patients who has recurrence of CRA(colorectal adenoma) during or after chemotherapy with metformin or placebo.
one year, two years
All polypoid lesions incidence rate
one year, two years
CRC incidence rate
one year, two years
low-dose metformin, 250mg/day
high-dose metformin, 500mg/day
placebo
Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology & Hepatology, Ministry of Health
Shanghai, Shanghai Municipality, 200001, China
Jing-Yuan Fang, Professor
Shanghai Jiao Tong University School of Medicine
First Submitted
November 29, 2020
First Posted
May 13, 2021
Study Start
August 1, 2020
Actual (reported)Placebo
Contact the study team to confirm eligibility.
Primary Completion
November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 13, 2021
Record last verified: 2021-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: